Effient Labeling Could Give Edge Against Plavix Through Pharmacogenetics

FDA cleared Lilly/Daiichi Sankyo's oral platelet inhibitor Effient (prasugrel) at both 5 mg and 10 mg doses on July 10, with a carefully constructed label that reflects the level of regulatory consideration - and negotiation - that went into the approval